ArticleScientific reports2017
Bacteriophages from ExPEC Reservoirs Kill Pandemic Multidrug-Resistant Strains of Clonal Group ST131 in Animal Models of Bacteremia.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06559618 (A Phase 1B Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria), which is not on this map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1B Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria
Who cites it
50 citing papers in PubMed, 69 citations in OpenAlex.
- Rapid phage susceptibility determination using a semi-automated bioluminescent ATP assay.Microbiology spectrum · 2026Article
- Phage as a prospective arsenal against superbugs.Molecular biology reports · 2026Review
- Isolation and therapeutic potential of phage vB_EcoM_GXW16 against a drug-resistant avian pathogenic Escherichia coli strain.Poultry science · 2026Article
- Bacteriophage-mediated reduction of uropathogenicInfection and immunity · 2026Article
- Discovery and characterization of a novelPHAGE (New Rochelle, N.Y.) · 2026Article
- Isolation and characterization of novel phages for control of the phytopathogen Pseudomonas marginalis.Applied microbiology and biotechnology · 2025Article
- Bacteriophage-mediated reduction of uropathogenicbioRxiv : the preprint server for biology · 2025Article
- A Phylogenetic Host-Range Index Reveals Ecological Constraints in Phage Specialisation and Virulence.Molecular ecology · 2025Article
- Human bladder organoids model urinary tract infection and bacteriophage therapy.bioRxiv : the preprint server for biology · 2025Article
- Macrophage-induced reduction of bacteriophage density limits the efficacy of in vivo pulmonary phage therapy.Nature communications · 2025Article
- Phage-induced protection against lethal bacterial reinfection.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Macrophage-induced reduction of bacteriophage density limits the efficacy ofbioRxiv : the preprint server for biology · 2025Article
- Evolutionary responses of Escherichia coli to phage pressure: insights into mucoidy and colanic acid overexpression.BMC genomics · 2025Article
- In Vitro Activity of Bacteriophages Against Ocular Methicillin-resistant S. aureus Isolates Collected in the US.Ophthalmology and therapy · 2025Article
- Characterization and genome analysis of lytic Vibrio phage VPK8 with potential in lysing Vibrio parahaemolyticus isolates from clinical and seafood sources.Virology journal · 2025Article
- Phage Therapy as a Rescue Treatment for RecurrentViruses · 2025Article
- Construction and characterization of DNA libraries from cultured phages and environmental viromes.Applied and environmental microbiology · 2024Article
- The Expanding Mycovirome ofJournal of fungi (Basel, Switzerland) · 2024Review
- Article
- Phage-Mediated Digestive Decolonization in a Gut-On-A-Chip Model: A Tale of Gut-Specific Bacterial Prosperity.Viruses · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Multi-drug resistant (MDR) enteric bacteria are of increasing global concern. A clonal group, Escherichia coli sequence type (ST) 131, harbors both MDR and a deadly complement of virulence factors. Patients with an immunocompromised system are at high risk of infections with these E. coli and there is strong epidemiologic evidence that the human intestinal tract, as well as household pets, may be a reservoir. Here, we examine if phages are an effective treatment strategy against this clonal group in murine models of bacteremia that recapitulate clinical infections. Bacteriophages isolated from known E. coli reservoirs lyse a diverse array of MDR ST131 clinical isolates. Phage HP3 reduced E. coli levels and improved health scores for mice infected with two distinct ST131 strains. Efficacy was correlated to in vitro lysis ability by the infecting phage and the level of virulence of the E. coli strain. Importantly, it is also demonstrated that E. coli bacteremia initiated from translocation across the intestinal tract in an immunocompromised host is substantially reduced after phage treatment. This study demonstrates that phage, isolated from the environment and with little experimental manipulation, can be effective in combating even the most serious of infections by E. coli "superbugs".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.